A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

Phase 1 Completed 8 enrolled Janssen Research & Development, LLC

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of the study is to measure the whole-body distribution and radiation dosimetry of \[18F\]JNJ-64511070 in healthy male participants by positron emission tomography (PET) (Part A); and to measure the uptake, binding, distribution, and washout of \[18F\]JNJ-64511070 in the brain of healthy male participants by PET and to model tissue specific kinetics of \[18F\]JNJ-64511070 with the appropriate arterial input function (IF) (Part B).

Timeline

Start: 2017-09-12
Primary completion: 2018-02-06
Completion: 2018-02-06

Publications

Koole M, Schmidt ME, Hijzen A, Cohilis M, Vandermeulen C, Serdons K, Celen S, Bormans G, Maher M, Szardenings AK, Zhang W, Kolb H, de Hoon J, Van Laere K. Dosimetry and kinetic modelling of [18F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-gamma8 receptors in the human brain. Eur J Nucl Med Mol Imaging. 2025 Dec;53(1):491-504. doi: 10.1007/s00259-025-07428-3. Epub 2025 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[18F]JNJ-64511070	Diagnostic / imaging agent	185 mbq	Intravenous

Indications

No indication recorded.